Last reviewed · How we verify
mIRV
mIRV is a multivalent respiratory syncytial virus (RSV) vaccine that stimulates immune responses against RSV to prevent infection and disease.
mIRV is a multivalent respiratory syncytial virus (RSV) vaccine that stimulates immune responses against RSV to prevent infection and disease. Used for Prevention of respiratory syncytial virus (RSV) infection in adults and older adults.
At a glance
| Generic name | mIRV |
|---|---|
| Sponsor | Pfizer |
| Drug class | Vaccine |
| Target | Respiratory syncytial virus (RSV) antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
mIRV is a recombinant RSV vaccine candidate designed to induce both humoral and cellular immunity against multiple RSV antigens. By presenting multiple RSV epitopes, the vaccine aims to provide broad protection against RSV infection across different age groups and RSV strains.
Approved indications
- Prevention of respiratory syncytial virus (RSV) infection in adults and older adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
Key clinical trials
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (PHASE2)
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (PHASE3)
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine (PHASE2)
- Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PHASE2)
- Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mIRV CI brief — competitive landscape report
- mIRV updates RSS · CI watch RSS
- Pfizer portfolio CI